Gouty arthritis
Conditions
Interventions
Anti-IL-1ß monoclonal antibody group:Voxinqibizumab 200mg was administered subcutaneously
Compound Betamethasone group:Compound betamethasone 7mg was given intramuscularly
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with diagnosed gout: meeting the 2015 ACR/EULAR classification criteria for gout 2. Age 18-80 years old 3. At least 2 acute gout attacks in the past 12 months 4. CKD stage 3-4-5 (eGFR = 50mm 6. Inadequate/irresistible response to non-steroidal anti-inflammatory drugs (NSAIDs) and/or colchicine: including: allergy, gastrointestinal reactions (such as nausea, diarrhea, dyspepsia, etc.), elevated liver and kidney function, agranulocytosis, thrombocytopenia; poor efficacy of joint pain treatment, etc. 7. Signed informed consent form, agreeing to participate in this study
Exclusion criteria
Exclusion criteria: 1.Active complications: Active infection, active gastrointestinal bleeding, or severe immunosuppression. 2.Recent cardiovascular events: Serious cardio-cerebrovascular events within the last 6 months. 3.Hypersensitivity: Known allergy to any components of the study medications. 4.Pregnancy/Lactation: Women who are pregnant, breastfeeding, or planning to become pregnant. 5.General Ineligibility: Poor compliance, psychiatric disorders, or any other conditions that, in the investigator’s judgment, make the patient unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to First Gout Flare; | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety;Renal function;Living Care score; | — |
Countries
China
Contacts
Public ContactYu Wang
Peking University First Hospital
Outcome results
None listed